What question did this study set out to answer?

The study evaluates the impact of CNS disease status on survival outcomes in pediatric acute myeloid leukemia (AML).

December 8, 2025Blood

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

View Full Paper

Ask AI

Bookmark

Authors

Analysis finds delayed LP and HSCT reduce CNS relapse in pediatric AML patients, indicating key treatment implications.

The study evaluates the impact of CNS disease status on survival outcomes in pediatric acute myeloid leukemia (AML).
Patients classified based on CNS status (CNS1, CNS2, CNS3) using diagnostic lumbar puncture.
Comparison of outcomes from COG trial AAML1831 to previous trials AAML0531/1031.
Assessment of treatment outcomes including intrathecal chemotherapy and hematopoietic stem cell transplant.
CNS status significantly predicts event-free survival (EFS) in pediatric AML patients.
Delaying lumbar puncture improved identification of CNS disease with notable reduction in negative cases.
Patients with HSCT showed lower cumulative incidence of CNS relapse compared to those receiving chemotherapy alone.

Pollard et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark